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Abstract: Stem cell research has been widely studied over the last few years and has attracted increasing attention from 
researchers in all fi  elds of medicine due to its potential to treat many previously incurable diseases by replacing damaged cells 
or tissues. As illustrated by hematopoietic stem research, understanding stem cell diff  erentiation at molecular levels is essential 
for both basic research and for clinical applications of stem cells. Although multiple integrative analyses, such as genomics, 
epigenomics, transcriptomics and proteomics, are required to understand stem cell biology, proteomics has a unique position in 
stem cell research. For example, several major breakthroughs in HSC research were due to the identifi  cation of proteins such as 
colony-stimulating factors (CSFs) and cell-surface CD molecules. In 2007, the Human Proteome Organization (HUPO) and the 
International Society for Stem Cell Research (ISSCR) launched the joint Proteome Biology of Stem Cells Initiative. A systematic 
proteomics approach to understanding stem cell diff  erentiation will shed new light on stem cell biology and accelerate clinical 
applications of stem cells.
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“multipotency”). Stem cells are largely categorized into two 
groups, ES cells and adult stem cells. Although these two 
types of stem cells have different sets of advantages and 
disadvantages, they both may be valuable sources for the 
future cell therapy.
ES cells have many advantages as a cell source for 
regenerative therapy. Given the appropriate environmental 
conditions, they can be coaxed into forming most cell types 
in the body and can provide unlimited amounts of cells 
for cell therapy. However, their applications for human 
treatment require special safety precautions. One concern 
is the potential risk of genomic abnormality (Draper et al., 
2004; Maitra et al., 2005) and tumor formation (Vogel 2005). 
Other concerns associated with ES cell-mediated therapy 
are immune rejection of transplanted tissue, difficulty in 
achieving homogeneous cell populations aft  er diff  erentiation, 
and ethical controversy resulting from the destruction of 
embryos. Many scientists believe that there still exists a great 
deal of social and scientifi  c uncertainty surrounding ES cell-
mediated cell therapy, which requires more extensive and 
Stem cells: deﬁ  nition and clinical relevance   
Currently, stem cells are widely and intensively studied 
in all fi  elds of medicine and science due to their potential to 
treat many incurable diseases. At the same time, there have 
been a wide range of social and ethical concerns on using 
human embryonic stem cells (ES cells) for research or therapy 
purposes because their derivation requires the destruction of 
embryos.
Stem cells are functionally defined as undifferentiated, 
primitive cells that retain the capability of indefinitely 
reproducing themselves (“self-renewal”) and also have 
the ability to generate multiple types of cells upon proper 
signals from internal and external cues (“pluripotency” or Anat Cell Biol 43:1~14, 2010 Sung-Min Ahn, et al 2
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thorough study. 
In contrast, adult stem cells have been used for cell therapy 
for quite a long time. For example, bone marrow transplant 
has been used to treat leukemia more than 10 years. Thus 
far, more than 70 different diseases and injuries have been 
successfully treated with adult stem cells. These include a 
number of blood-related abnormalities, immunological 
dysfunctions, cancers, stroke, brain trauma, juvenile diabetes, 
Parkinson’s disease, blindness, spinal cord injuries and so 
on. More than 1200 clinical trials with adult stem cells have 
been approved by the U.S. Food and Drug Administration 
(FDA). There are several reasons that account for the wide 
use of adult stem cells in clinical applications. Th  ese  include 
very little chance of tumor formation, no ethical problems, 
the possibility of autologous transplantation, which causes 
no immune rejection, and easy diff  erentiation into a certain 
specifi  c lineage of cells. 
However, the prevailing belief that adult stem cells do not 
form tumors needs thorough reevaluation. Th   ere has been a 
recent report that adipose tissue-derived human mesenchymal 
stromal cell (MSC) populations can immortalize and 
transform spontaneously. This MSC-TMC (Transformed 
Mesenchymal cells) transition happened aft  er in vitro culture 
and expansion (Rubio et al., 2005). Furthermore, several other 
reports argue that some cancer cells are derived from adult 
stem cells in the body (Marx 2003; Pardal et al., 2003; Clarke 
& Fuller, 2006). Currently, safety issues and techniques for in 
vitro expansion of the cells may be the two most important 
topics to develop additional successful cell therapies using 
adult stem cells.
Future studies should be focused on overcoming three 
major obstacles that hinder successful stem cell therapy. 
First, obtaining autologous cell sources is required to avoid 
immune rejection. Th   is issue is especially serious for ES cell-
mediated cell therapy. One way to get around the immune 
problem is to generate pluripotent, ESC-like cells from the 
patient’s own cells either by cellular reprogramming or by 
Somatic Cell Nuclear Transfer (SCNT). Recently, there have 
been great achievements in generating induced pluripotent 
stem cells (iPS cells) (Takahashi et al., 2007; Yu et al., 2007), 
although more work is needed to bring iPS cells to patient 
treatment. At the same time, the recent success of SCNT in 
rhesus macaque primates (Byrne et al., 2007) raises a hope 
that it may soon also be possible in humans. Establishing a 
stem cell therapeutic bank (Taylor et al., 2005) and autologous 
cell therapy using adult stem cells would be other options to 
solve the immune rejection problem. 
Th   e second issue is preventing tumor formation. Th  is  issue 
is especially serious for clinical use of ES cells. Since tumor 
formation is thought to be caused by residual undiff  erentiated 
ES cells, the development of methods that remove these 
remnant ES cells is of great importance. 
The third issue is establishing efficient protocols to 
differentiate ES cells into the cell types of interest. This will 
increase the efficacy of cell therapies, reduce side effects 
caused by the presence of unwanted cell types, and minimize 
tumor formation resulting from remnant undiff  erentiated ES 
cells. 
Multiple aspects of understanding stem cell 
diﬀ  erentiation
Each cell type in the human body, including stem cells, has 
a unique information architecture maintained by cell-specifi  c 
transcriptional regulatory states that lead to differential 
expression of genes (Davidson 2006). According to the 
International Human Genome Consortium, the number 
of genes in the human genome is estimated to be between 
20,000 and 25,000. The 274 different kinds of cells in the 
human body are defined by combinatorial expression of 
this limited number of genes (Wenick & Hobert, 2004). Th  e 
transcriptional regulatory circuitry in cells is maintained by 
the dynamic interplay of multiple regulatory mechanisms, 
including epigenetic, transcriptional, posttranscriptional, 
and posttranslational regulation of gene expression (Cheng et 
al., 2005). Th   erefore, understanding stem cell diff  erentiation 
requires an overall understanding of the elaborate web 
of regulations at the levels of the genome, epigenome, 
transcriptome, microRNAome, and proteome. 
Transcription factors (TFs) are good examples of how 
multiple regulatory mechanisms act in concert. TFs are core 
elements of the transcriptional regulatory circuitry (Boyer 
et al., 2005). In theory, it is possible to turn a brain cell into 
a liver cell by transferring all TFs in a liver cell to a brain cell 
while inactivating all brain-specifi  c TFs (Reik 2007). A recent 
study that shows induction of pluripotent stem cells from 
fi  broblasts by defi  ned TFs also supports this idea (Takahashi 
& Yamanaka, 2006). Given their importance in cell 
specification and function, it is not surprising that multiple 
regulatory mechanisms are involved in the regulation of 
TFs. For example, when embryonic stem cells are induced to Genomics and proteomics in stem cell research
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diff  erentiate, Oct-3/4, a main regulator of human embryonic 
stem cell pluripotency and self-renewal (Boyer et al., 2005), 
is epigenetically repressed through histone modifications, 
followed by DNA methylation at the promoter region 
(Feldman et al., 2006). Once transcribed, mRNAs of TFs may 
be posttranscriptionally regulated by microRNAs (Bartel 
2004). According to a recent computational analysis, many 
TFs are target hub genes of microRNAs, and TF-microRNA 
pairs may coregulate large sets of common targets (Shalgi et 
al., 2007). Posttranslational modifications (PTMs) provide 
another layer of regulation. It is well known that TFs, such 
as STATs and Smad 2/3, require PTMs for their nuclear 
localization and regulatory activities (O’Shea et al., 2002; 
Elliott & Blobe, 2005).   
In this section, we aim to provide a concise review of 
multiple aspects of understanding and studying stem cell-
differentiation: genomics, epigenomics, transcriptomics, 
microRNAomics, and proteomics. In the next section, we will 
specifically discuss the potential roles of proteomics in the 
fi  eld of stem cell biology. 
Regulatory genome 
The human genome encodes 20,000~25,000 protein-
coding genes that account for only 1.5% of the nearly three 
billion base pairs of the genome (Stein 2004). In addition 
to protein-coding regions, a substantial portion of the non-
protein-coding regions in the genome, which are poorly 
defi  ned, is transcribed (Th   e EPC 2004). Non-coding RNAs (i.e. 
transcripts of non-protein-coding genes) include microRNAs, 
small regulatory RNAs, and tens of thousands of longer 
transcripts with unknown functions (Mattick & Makunin, 
2006). 
In addition to coding sequences, the genome contains 
regulatory architecture called cis-regulatory modules (CRMs) 
that consist of a set of TF-binding sites (TFBSs) located in the 
vicinity of the gene being regulated (Blanchette et al., 2006). 
As previously described, diff  erentiation requires the institution 
of new transcriptional regulatory states. Th   e CRMs, which are 
“information processing devices hardwired into the genome,” 
read the given transcriptional regulatory states, process that 
information, and instruct the basal transcription apparatus 
to turn the gene on or off (Davidson 2006). Therefore, the 
human genome is a self-executing set of instructions that not 
only encodes proteins and non-coding RNAs, but also directs 
where, when, and how much each of these products will be 
expressed, ultimately producing the complex body plan of the 
adult organism (Howard & Davidson, 2004). One of the most 
widely and intensively studied examples of the regulatory 
genome in stem cells is the regulatory network of Oct4, Sox2, 
Nanog and Klf4 in embryonic stem cells (Nichols et al., 1998; 
Avilion et al., 2003; Chambers et al., 2007). Activation of 
these genes is key to maintaining pluripotency in embryonic 
stem cells. Another group of genes is also reported as related 
to neural stem cells and their progenitor cells (Wang et al., 
2008). These examples of the regulatory genome have been 
a focus of stem cell research because of their importance 
in maintaining pluripotency. Scientists are still trying to 
identify novel regulatory genome components that are 
involved in maintaining self renewal of stem cells or lead to 
diff  erentiation.
Epigenetic aspects of stem cell diff  erentiation
Genetic information is stored in the DNA sequence using 
a four digit code (i.e., A, G, T, C), and the genome is the 
complete set of information in an organism’s DNA (Alberts 
2002). Epigenetic information is heritable information that 
is not encoded in the DNA sequence but still affects gene 
expression (Russo et al., 1996). In eukaryotes, the DNA 
molecule is wrapped around a core of eight histones (two 
H2A, H2B, H3, and H4 histones) to form nucleosomes, which, 
in turn, are packaged into chromatin (Luger et al., 1997). 
Epigenetic information is stored by covalent modifi  cations of 
the DNA or its packaging histones. Th   erefore, an epigenome 
can be defi  ned as the sum of heritable covalent modifi  cations 
of the chromatin, ‘the dynamic template of the genetic 
information’. Th   e human genome is organized into accessible 
(euchromatic) or inaccessible (heterochromatic) subdomains 
by epigenetic changes (Arney & Fisher, 2004) (Fig. 1). 
“Development is, by definition, epigenetic” (Reik 2007). 
Epigenetic mechanisms provide both stable and fl  exible gene 
regulation required for development. Histone modifications 
confer short-term, fl  exible regulation while DNA methylation 
confers long-term, stable silencing (Reik 2007). Since one 
genome can generate many epigenomes, the dynamic genetic 
templates created by the combination of a genome and a 
variety of epigenomes provide the basis of cell-type-specifi  c, 
unique gene expression profi  les.
DNA methylation: DNA methylation in mammalian cells 
refers to covalent modifi  cation of DNA by methylation of the 
cytosine, which occurs predominantly in CpG dinucleotides. 
DNA methylation has been implicated in a wide range of 
physiological and pathological processes such as genomic Anat Cell Biol 43:1~14, 2010 Sung-Min Ahn, et al 4
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imprinting, X chromosome inactivation, tissue-specifi  c gene 
expression, cellular diff  erentiation, carcinogenesis and aging 
(Jones & Takai, 2001; Bird 2002). Recent fi  ndings in animal 
cloning indicate that epigenetic reprogramming is important 
for successful cloning (Kang et al., 2001), which in turn 
support the idea that DNA methylation provides a specific 
cellular memory function in development (Bird 2002).
DNA methylation can affect gene transcription through 
two main mechanisms. Firstly, site-specifi  c DNA methylation 
may interfere with the binding to DNA of transcription 
factors (TFs) that activate gene transcription (Watt & 
Molloy, 1988). Secondly, DNA methylation attracts methyl-
CpG-binding domain (MBD) proteins that in turn recruit 
corepressor complexes involved in transcriptional silencing. 
Comparative sequence analysis using the sequence of MeCP2, 
the prototypical MBD protein, led to the identification of 
additional family members (MBD1, MBD2, MBD3, and 
MBD4) (Wade 2001). Interestingly, each MBD protein seems 
to have exclusive binding sites, which suggests that MBD 
proteins are not functionally redundant (Klose et al., 2005). 
As previously mentioned, DNA methylation is involved 
in the long term silencing of gene expression, which plays an 
important role in the regulation of pluripotency-associated 
genes (Reik 2007). For example, transcriptional repression 
of Oct-3/4 is first followed by histone H3 methylation 
on Lys 9, which leads to local heterochromatization and 
DNA methylation at the promoter region (Feldman et al., 
2006). The importance of this mechanism is manifested in 
cancers. According to one recent study, Oct-3/4 is expressed 
in adult human stem cells, tumor cells and cell lines, but 
not in differentiated cells (Tai et al., 2005). This evidence 
is consistent with the cancer stem cell hypothesis, which 
argues that tumors arise from small populations of cancer 
stem cells that originate from the transformation of normal 
stem cells (Pardal et al., 2003). According to the epigenetic 
progenitor origin of cancer theory, a modifi  ed version of the 
cancer stem cell hypothesis, the first step to carcinogenesis 
is epigenetic disruption of stem cells or progenitor cells, 
which is demonstrated as changes in DNA methylation 
(Feinberg et al., 2006). Thus, understanding stem cell 
differentiation from an epigenetic perspective may provide 
new insights on carcinogenesis. Recently, detailed analysis 
of DNA methylation in the maintenance of pluripotency has 
become a popular area of study to better understand the basic 
mechanisms underlying this process in ES cells as well as in 
iPSCs (Bhutani et al., 2009). 
Histone code: As previously described, histones are not 
merely DNA packaging molecules but also important carriers 
of epigenetic information. Epigenetic information is stored 
in histones by chemical modifi  cations of the N-terminal tails 
of core histones, including acetylation, phosphorylation, 
methylation, and ubiquitination. 
Histone modifications can affect the chromatin template 
and therefore transcription through three main mechanisms: 
Cis-effects, trans-effects, and histone replacements. Firstly, 
histone modifi  cations can alter intranucleosomal interactions 
by changing the physical properties of modified histone 
tails, such as electrostatic charges (cis-effects). These 
intranucleosomal structural changes can aff  ect the accessibility 
of the DNA contained on that nucleosome to transcriptional 
factors. For example, phosphorylation of the linker histone 
H1, which reduces the electrostatic binding of H1 to DNA in 
chromatin, can repress transcription (Dou & Gorovsky, 2000). 
Secondly, histone modifications are recognized (or read) by 
modifi  cation-specifi  c binding partners (trans-eff  ects), which 
mediate down-stream chromatin-modulating events. For 
example, methylation of lysine 9 on histone H3 is read by the 
Fig. 1. One genome, many epigenomes. Every somatic cell in the human 
body has almost the same genetic information. Epigenetic changes 
defi  ne accessibility to the genetic information, thus creating cell-type-
specifi  c, dynamic genetic templates. In general, stems cells have more 
open, accessible chromatin structures than diff  erentiated cells.Genomics and proteomics in stem cell research
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chromodomain of heterochromatin protein 1 (HP1), which 
is involved in both maintenance and somatic inheritance 
of transcriptionally silent heterochromatin (Bannister et 
al., 2001). Lastly, histone modifications can recruit ATP-
dependent chromatin remodelers that shuffl   e histone variants 
into and out of chromatin. The replacement of histone 
variants plays important roles in transcriptional regulation. 
For example, the replacement of H3 with the histone variant 
H3.3 is associated with active chromatin and coupled to 
transcription (Ahmad & Henikoff  , 2002; Schwartz & Ahmad, 
2005). 
The “histone code” hypothesis has evolved from 
the recognition of the combinatorial nature of histone 
modifications that can generate synergistic or antagonistic 
interaction affinities for chromatin-associated proteins 
(Jenuwein & Allis, 2001). According to this hypothesis, 
histone modifications can act sequentially, in that a given 
modification of a specific histone residue is required for 
subsequent modifications of the same histone or another 
histone molecule (Margueron et al., 2005). For example, 
ubiquitination of histone H2B on lysine 123 is required for 
the methylation of histone H3 on lysine 4, which leads to 
transcriptional repression (Dover et al., 2002). The histone 
code hypothesis also implies that multiple signaling pathways 
converge on chromatin through histone modifications, the 
combination or summation of which are ‘read’ by chromatin-
associated proteins (Nightingale et al., 2006). The presence 
of local binary switches (e.g., the ‘methyl/phos switch’ on H3 
Lys 9/Ser 10) and modifi  cation cassettes (i.e. the combination 
of modifications in short clusters with distinct biological 
readouts) support this hypothesis (Fischle et al., 2003). One of 
the most studied modifi  cations of the histones is acetylation. 
There are a few reports describing histone acetylation as 
important in human embryonic stem cell pluripotency (Lee et 
al., 2004, Bernstein et al., 2006). Th   is epigenomic control has 
been a focus of stem cell research for many years, with DNA 
methylation and miRNA studies of transcriptional regulation 
in maintaining self-renewal and regulating diff  erentiation. 
Transcriptomic approach to understand stem cell 
diff  erentiation
Microarray technology has revolutionized the field of 
transcriptomics, enabling biologists to perform global gene 
expression analyses (Chang et al., 2006). Aft  er the isolation of 
various stem cells, including ESCs, NSCs, and HSCs, one of 
the first questions addressed by microarray technology was 
identifying whether there are intrinsic molecular programs 
shared by all stem cells that define “stemness.” The search 
for stemness is based on the hypothesis that stem cells have 
to respond in similar ways to regulate self-renewal and 
differentiation, irrespective of their lineal origin (Cai et al., 
2004).
Th  e  fi  rst studies comparing the transcriptomic profi  les of 
stem cells raised both enthusiasm and confusion. Ramalho-
Santos et al. (Ramalho-Santos et al., 2002) and Ivanova et al. 
(Ivanova et al., 2002) compared transcriptional profiles of 
ESCs, HSCs, and NSCs, each identifying a list of genes that 
are likely to reveal core stem cell properties. Interestingly, the 
number of overlapping genes between the two studies was 
minimal (only 15 genes), and most of the stemness genes 
from both groups were not exclusively expressed in NSCs. 
Th  ese  fi  ndings raised two fundamental questions: 1) whether 
stemness can be defined at the genetic level (Fortunel et 
al., 2003), and 2) whether a specific combination of genes 
rather than individual genes endows stemness (Burns & 
Zon, 2002). These studies not only provided a first glimpse 
of stemness networks, but also revealed critical issues in the 
transcriptomic profi  ling approach to defi  ning stemness.
microRNA
Basic concepts: Non-coding RNAs or nonprotein-coding 
RNAs control various levels of gene expression in physiology 
and development, including chromatin architecture/
epigenetic memory, transcription, and RNA splicing, editing, 
translation and turnover (Mattick & Makunin, 2006). 
MicroRNAs (miRNAs) are a class of non-coding RNAs that 
are about 22 nucleotides in length and play important roles 
in the regulation of target genes (Bartel 2004). According to 
current estimates, miRNAs account for ~1% of predicted 
genes in higher eukaryotic genomes and regulate up to 
10~30% of genes (Cui et al., 2006).
miRNAs regulate gene expression by either of two post-
transcriptional mechanisms, depending on sequence 
complementarity; miRNA induces cleavage of the mRNA 
(100% complementarity) or represses translation by binding 
to the 3’ UTR (less complementary) (Pasquinelli et al., 2005). 
In plants, miRNAs base pair with target mRNAs by precise or 
nearly precise complementarity, leading to direct cleavage and 
destruction of the targets. In contrast, most animal miRNAs 
are less complementary to their target mRNAs and inhibit Anat Cell Biol 43:1~14, 2010 Sung-Min Ahn, et al 6
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protein synthesis while preserving the stability of the target 
mRNAs. According to the combinatorial rheostat model of 
gene expression micromanagement by miRNAs, especially 
in animals, the combinatorial binding of miRNAs with 
diff  erent eff  ective concentrations in diff  erent cell types leads 
to resistance changes (i.e., resistance to translation), thereby 
fine-tuning the level of protein that is produced (Bartel & 
Chen, 2004).
The imprecise base pairing between the typical animal 
miRNA and a target mRNA suggests that animal miRNAs 
may regulate a wide repertoire of different mRNAs. This 
hypothesis was supported by a recent study using microarray 
analysis, in which transfection of tissue-specific miRNAs 
downregulated a large number of target mRNAs (e.g., 
miR-124 downregulated 174 genes) (Lim et al., 2005). 
Interestingly, there are some apparent trends in the types of 
genes regulated by miRNAs. For example, in Drosophila, the 
target genes of miR-277 are enriched for functionally related 
enzymes involved in the catabolism of leucine, isoleucine and 
valine, suggesting that miR-277 acts as a ‘metabolic switch’ 
of this biochemical pathway (Stark et al., 2003). Certain 
miRNAs (e.g., miR-34a-c) are important components of 
signaling pathways, such as the p53 network (He et al., 2007). 
miRNAs are also known to be involved in the regulation of 
various biological processes, including apoptosis (Xu et al., 
2004), animal development (Wienholds & Plasterk, 2005), 
physiological function (e.g., insulin secretion) (Poy et al., 
2004), and diff  erentiation (Chen et al., 2004). 
miRNA and stem cell differentiation: From the per-
spective of stem cell biology, miRNAs are attractive regulatory 
molecules, as they provide an effi   cient means for coordinating 
the action of many functionally related target genes (Cheng 
et al., 2005). The highly tissue-specific expression of most 
miRNAs also suggests that miRNAs play important roles in 
differentiation and maintenance of cell identity (Wienholds 
et al., 2005). As previously described, TFs are core elements 
of the transcriptional regulatory circuitry that determines cell 
specifi  cations (Davidson 2006). Th   erefore, the fact that many 
TFs are target hub genes of miRNAs underscores the roles of 
miRNAs in the transcriptional regulatory circuitry and cell 
specifications. miRNAs involved in differentiation not only 
target TFs such as Nanog, Smad1, and c-Myb (Luzi et al., 
2007; Xiao et al., 2007), but also form elaborate regulatory 
loops with TFs, which provides a mechanism for determining 
stable end states. For example, Johnston et al. (Johnston et al., 
2005) showed that two miRNAs and their TF targets act in a 
double-negative feedback loop to control neuronal cell fate 
decision, and miRNAs function as developmental switches in 
such regulatory loops. Yoo and Greenwald (Yoo & Greenwald, 
2005) also showed a similar feedback loop in which a miRNA 
works as a developmental switch for mutually exclusive 
expression of two cell-fate-determining genes. In this model, 
the protein encoded by the fi  rst gene switches on a miRNA, 
which in turn switches off expression of the second gene 
(Plasterk 2006). 
Recently, several reports has been published regarding 
novel miRNAs and their function in both maintaining 
pluripotency and self renewal (Sanosaka et al., 2009; Liu & 
Zhao, 2009, Judson et al., 2009). 
 
Stem cell proteomics: the road ahead 
Why stem cell proteomics? 
Major breakthroughs in HSC research were made by the 
identification of proteins such as colony-stimulating factors 
(CSFs) and cell-surface CD molecules. Proteins, key players 
in the cell, have diverse features that are not predictable 
from gene sequences or transcript levels. For example, 
posttranslational modifications (PTMs), protein-protein 
interactions, and subcellular locations affect the function 
and activity of proteins, but these are not predictable using 
genomics or transcriptomics technology.
Both basic and clinically oriented stem cell research are 
confronted with many open questions that can be most 
efficiently answered by proteomics. For instance, the cell 
surface proteins and signaling cascades of stem cells and 
their differentiated progenies are largely unknown, as are 
the differentiation-specific proteins that can be used as 
biomarkers of the intermediate or terminal steps of cell 
differentiation, or discriminate tumorigenic cells from the 
pool (Krijgsveld et al., 2008).  
According to Metcalf, one of the pioneers of CSF research, 
the most formidable technical challenge in identifying CSFs 
was their purification (Metcalf 1991). Given the current 
status of proteomics technology, a project like that of CSF 
purification and identification can now be completed in six 
months rather than years or decades. Th   e biggest challenge we 
now face is the systematic and optimized use of proteomics 
technology to decipher stem cell biology. 
   Genomics and proteomics in stem cell research
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Stem cell proteomics: the road ahead
Finding CDs: the membrane proteome and beyond 
Membrane proteins perform most of the specific functions 
of the plasma membrane (Alberts 2002). According to 
bioinformatic analyses, 20~30% of all open reading frames 
in the genome are predicted to encode membrane proteins 
(Wallin & von Heijne, 1998). Membrane proteins represent 
more than two-thirds of drug targets (Hopkins & Groom, 
2002), and they are essential to understand the underlying 
mechanisms of various biological functions. For example, our 
understanding of immune function is based on recognition 
of only 10~20% of leukocyte membrane proteins (Zola & 
Swart, 2003). In stem cell research, membrane proteins are 
important not only for understanding stem cell biology, but 
also for their clinical application.
The first membrane proteomics initiative: the Human 
Leukocyte Differentiation Antigens Workshop (HLDA), 
arguably the first systematic membrane proteomics 
consortium, was initiated in 1982, before the word 
‘proteomics’ was even coined in 1995. HLDA aimed to bring 
order to the chaos caused by the generation of large numbers 
of monoclonal antibodies reactive against leukocyte cell-
surface molecules, each with unknown molecular targets 
and different associated nomenclatures (Zola et al., 2005). 
Through the organized efforts of HLDA, many cell-surface 
molecules with important functions in leukocyte biology 
were identified and characterized under the CD (“cluster of 
differentiation”) system, many of which are currently used 
widely as diagnostic reagents (e.g., CD3, CD4), and as the 
basis for therapeutic agents (e.g., CD3, CD20) (Zola & Swart, 
2003). In 2005, the HLDA council changed the name of 
the organization to Human Cell Differentiation Molecules 
(HCDM) to reflect their broader objectives: to extend the 
focus from leukocytes to other cell types and to broaden 
the organization’s scope from cell-surface molecules to any 
molecule whose expression reflects differentiation (Zola et 
al., 2005). Therefore, CD molecules now include proteins 
involved in diff  erentiation as well as membrane proteins. 
Aft  er the development of protein sequencing technology, 
such as Edman degradation (Edman 1960) and mass 
spectrometry (Hunt et al., 1986), monoclonal antibodies 
no longer represent the primary tool for discovering new 
proteins, but combining knowledge of the human genome 
sequence, powerful bioinformatics, and cloning technologies 
allows for new opportunities in antibody proteomics. In 
addition, CD antibody microarrays, used for high-throughput 
screening of CD antigens in cells and tissues, provides a good 
example of how the conventional CD approach can be used 
in conjunction with high-throughput proteomics technology 
(Woolfson et al., 2006).
Antibody proteomics: Antibody proteomics, one of 
the major initiatives of the Human Proteome Organization 
(HUPO), is defined as the systematic generation and use 
of protein-specific antibodies to functionally explore the 
proteome (Uhlen & Ponten, 2005). Agaton et al. (Agaton 
et al., 2003) showed that Protein Epitope Signatures Tags 
(PrESTs), unique epitopes present in native proteins, can 
be used as antigens and affinity ligands for cost-effective 
generation of highly selective, mono-specific antibodies 
or affinity-purified polyclonal antibodies. Currently, 
this approach has been extensively used to construct a 
comprehensive, antibody-based protein atlas of expression 
and localization profiles in human normal and cancer 
tissues (Uhlen et al., 2005). As monoclonal antibodies have 
been systematically validated for leukocyte biology through 
HLDA (currently HCDM), the resources developed by the 
antibody proteomics initiative can be systematically used for 
stem cell research. For that purpose, well-defined panels of 
stem cells and their derivatives are required. Once prepared, 
these panels of cells can be efficiently screened using high-
throughput cell microarray (tissue microarray) methods. Th  is 
approach allows for detection of novel CD molecules involved 
in the diff  erentiation of a variety of stem cells.
MS-based membrane proteomics: As previously 
mentioned, the antibody-based approach has both success 
and promise in identifying novel proteins, especially 
membrane proteins. However, the antibody-based approach 
has intrinsic limitations because it is an indirect method for 
characterizing proteins, and there can be cross-reactivity in 
antibody-antigen interactions (Bentley et al., 1994). Also, the 
antibody-based approach cannot provide much information 
about posttranslational modifi  cations that may be important 
for protein function. 
In contrast, a mass spectrometry (MS)-based approach 
allows direct sequencing of peptides and proteins, and 
it can be used either as a method complementing the 
antibody-based approach or for direct identification and 
characterization of CD molecules. Firstly, MS can be used to 
identify molecular targets of antibodies (e.g. identifi  cation of 
immunoprecipitated proteins). Furthermore, even epitope 
mapping of antibodies is possible using MS (Yu et al., 1998). 
Secondly, a MS-based approach, coupled with membrane Anat Cell Biol 43:1~14, 2010 Sung-Min Ahn, et al 8
www.acbjournal.com doi: 10.5115/acb.2010.43.1.1
protein preparation and separation technologies, can be used 
to directly identify and characterize membrane proteins from 
cells and tissues (Wu et al., 2003; Wu & Yates, 2003). In 2005, 
AOHUPO (Asia Oceania Human Proteome Organization) 
launched the Membrane Proteomics Initiative (MPI), which 
aims to develop methods for characterizing membrane 
proteomes, and to characterize the proteomics of specific 
membrane systems. Once phase I (technology development) 
and phase II (large-scale analysis of membrane proteomes) 
are finished, the methods and experiences from MPI can 
be readily utilized for more subtle areas, such as stem cell 
proteomics.   
Posttranslational modifications (PTMs): The high com-
plexity of the human proteome, consisting of ~300,000~ 
3,000,000 distinct protein forms, results from the 
diversification of genetic information at both the mRNA 
level and the protein level (Walsh 2006). Genetic information 
stored in ~30,000 genes is diversified through alternative 
splicing of primary mRNA transcripts at the mRNA level 
(Black 2003). Once translated, proteins are diversifi  ed through 
post-translational covalent changes termed PTMs (Krishna 
& Wold, 1993), and many important regulatory steps depend 
on proteins’ PTMs rather than on their expression levels 
(Levchenko 2005). 
PTMs play important roles in stem cell biology. Elliott 
et al. (Elliott et al., 2004) showed that ~21% of the proteins 
identified in murine R1 ES cells had PTMs, and several of 
them, including Ras-GTPase activating protein binding 
protein 1 and phosphoglycerate kinase, had not been 
previously associated with PTMs. Unwin et al. (Unwin et al., 
2006), revealed the importance of posttranslational control as 
a regulatory factor in primary hematopoietic stem cells. From 
the proteomics perspective, assaying changes in PTMs during 
stem cell diff  erentiation in a high-throughput fashion is a key 
to understanding the underlying mechanisms of stemness 
and diff  erentiation. 
Th   e determination of PTMs is one of the main challenges 
in proteomics research. However, recent developments 
in affinity-based enrichment and extraction methods, 
multidimensional separation technologies, and mass 
spectrometry (MS) now allow systematic investigation of 
PTMs. For example, histone PTMs have been extensively 
characterized by MS-based proteomics approaches (Pesavento 
et al., 2004; Th  omas  et al., 2006). Furthermore, emerging top-
down MS technology captures not only individual PTMs, 
but also their combinations present on the same protein 
molecule (Garcia et al., 2007; Taverna et al., 2007). Proteomics 
also allows for quantitative analysis of subproteomes with 
a specific PTM (e.g. the phosphoproteome (Reinders & 
Sickmann, 2005) and the methylproteome (Ong et al., 2004). 
For example, Kratchmarova et al. (Kratchmarova et al., 
2005) used MS-based approaches to quantitatively monitor 
tyrosine-phosphorylated proteins upon the differentiation 
of mesenchymal stem cells into bone-forming cells in 
response to growth factors. Recently, Van Hoof et al. (2009) 
successfully reported phospho-protein profiling during 
early differentiation of human embryonic stem cells, which 
enables the identifi  cation of key protein activations in specifi  c 
signaling pathways of the early differentiation process. 
This paper provides strong evidence of how PTM-based 
proteomics can contribute to understanding the mechanism 
of adaptor signaling at the stem cell level. This technique 
will likely be widely applied to mechanism-based research 
focusing on self-renewal and diff  erentiation processes of stem 
cells.  
Protein-protein interactions (PPI): A single protein may 
have diverse functions that are determined in the context of 
the network or functional module it belongs to (Sharan et al., 
2007). Th   e importance of PPI is well illustrated in the famous 
Myc-Max-Mad network in which different combinations 
of TFs lead to different functional outcomes (Baudino 
& Cleveland, 2001). With the help of proteomics and 
bioinformatics, a comprehensive map of protein interactions 
in human was recently created, which describes the sum of all 
potential protein interactions in humans (Gandhi et al., 2006). 
Since each of the ~274 diff  erent cell types in the human body 
has different protein expression profiles and thus different 
protein networks, understanding the unique protein network 
architecture of each cell type is a key to understanding stem 
cell diff  erentiation. 
As previously described, the transcriptional regulatory 
circuitry, in which TFs are core elements, determine cell 
specification and function. Therefore, it is important to 
understand protein interactions of transcription factors in 
order to understand the transcriptional regulatory circuitry. 
Kim et al. (Kim et al., 2006) showed that a small protein 
interaction network starting from Nanog, a central TF in ES 
cells, might serve as a functional module for maintaining ES 
cell pluripotency. Th   e diverse roles of TFs in both stem cells 
and diff  erentiated cells also indicate that their corresponding 
protein networks might differ. For example, in neural crest 
stem cells, Sox10, a high-mobility-group TF, maintains Genomics and proteomics in stem cell research
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pluripotency and inhibits neuronal differentiation (Kim 
et al., 2003). On the other hand, Sox10 is involved in the 
terminal diff  erentiation of myelin-forming oligodendrocytes 
(Stolt et al., 2002). The fact that Sox10 interacts with many 
TFs, forming diverse protein networks, may partly explain 
its contradictory roles in stem cells and differentiated cells 
(Wissmuller et al., 2006).            
Finding stem cell growth factors: secretome As men-
tioned earlier, understanding diff  erentiation is important both 
for basic research and clinical applications. In HSC research, 
the first major technical advance towards understanding 
hemopoiesis was the introduction of solid-state cultures 
of bone marrow and spleen cells (Bradley & Metcalf, 1966; 
Ichikawa et al., 1966). Then, the discovery of hemopoietic 
growth factors or colony-stimulating factors (CSFs) led to 
molecular level understanding of hemopoietic diff  erentiation, 
followed by clinical applications of CSFs (Metcalf 1991). 
The extensive purification required to achieve complete 
purification of each CSF illustrates the importance and 
usefulness of proteomics technology in discovering growth 
factors present in minute amounts. In the most diffi   cult case, 
enrichment of one million-fold was required for purifi  cation 
and characterization of a CSF (Metcalf 1991).  
As illustrated in HSC research, finding growth factors in 
the secretome is a critical step towards understanding and 
controlling stem cell-differentiation at the molecular level. 
Recently, a proteomics approach revealed the endodermal 
secretome network guiding stem cell cardiopoiesis from ES 
cells (Arrell et al., 2008). Evidence from normal and tumor 
cells also illustrate the linkage between signal transduction 
pathways and the secretome (Jacobs et al., 2006; Khwaja et al., 
2006). 
Most CSFs were purified from media conditioned by 
various human tumor cells, and it is noteworthy that tumors 
secreting CSFs include not only hemopoietic cancers such 
as a T-lymphoblast cell line (Gasson et al., 1984), but also a 
human squamous cell line from a lower oral cavity (Nomura 
et al., 1986) and a gastric cancer cell line (Baba et al., 1995), 
which are not related to hemopoiesis. Therefore, systematic 
screening of stem and cancer cell media, combined with 
extensive proteomic purification and characterization, may 
be required for high-throughput characterization of the 
growth factor repertoire of each stem cell line. Recently, Kang 
et al. (Kang et al., 2008) reported proteomic differences of 
various sized exosomes from human neural stem cells and 
its differentiated oligodendrocyte progeny. In the study, the 
authors separated exosomes with Field-Flow Fractionation by 
10 nm size diff  erences, and showed that this step was useful 
for reproducibly analyzing the proteomics changes. These 
promising results suggest that well-designed sampling strategy 
and analysis technologies should be further developed to 
achieve better yields in secretome-based proteomics.    
Perspectives
In 2007, the HUPO and ISSCR joint initiative, Proteome 
Biology of Stem Cells, was established as a collaborative 
platform bringing together stem cell biologists and researchers 
in proteomics (Heck et al., 2007; Krijgsveld et al., 2008). Th  e 
aim of the initiative is to effectuate the implementation of 
cutting edge proteomic technology in stem cell research to 
further our understanding of stem cell biology. Th   is has been 
prompted primarily by major breakthroughs in stem cell 
biology, the potential of stem cells for biomedical application, 
and the awareness that proteomics may be able to accelerate 
this progress further and possibly open yet unexplored 
areas of research. Over the last 2 years, acting groups of the 
initiative have started workshops to optimize protocols for 
hESC sampling, MS analysis, and bioinformatics analyses. Th  e 
initiative has successfully chosen hESC cells for initial study 
from the ES cell bank of the International Embryonic Stem 
Cell Consortium. Analysis of hESC membrane proteins will 
be started soon to standardize biomarker discovery, and this 
will help provide standard guidelines for stem cell proteomics. 
Th   e voyage to stem cell proteomics has already begun.
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